Southeast Asian stem cell leader Medeze launches voluntary conditional cash partial offer for 10% stake in SGX-listed Cordlife Group Limited

Medeze Group, a Thailand-listed company, plans to make a voluntary conditional cash partial offer to buy 10% of Cordlife Group’s shares. The offer price of S$0.25 per share is a 61.3% premium over the last traded price. Medeze sees this as an opportunity for long-term investment and potential collaborations with Cordlife for mutual business growth. The offer aims to provide Cordlife shareholders with a chance to exit at a premium. By acquiring a stake in Cordlife, Medeze hopes to explore synergies, expand market reach, and develop new products and services in the region.